Actively Recruiting
Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage
Led by Wright State University · Updated on 2025-08-11
20
Participants Needed
1
Research Sites
153 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In patients with bleeding from a brain aneurysm, severe headache is the most common complaint. However, the pain is difficult to treat. The use of standard pain medications is common, but pain control remains poor. Additionally, pain medicines have multiple side effects including sedation, interference with breathing, intestinal cramping, low blood pressure, and the risk of addiction. In the present study, the investigators will examine the use of a medication to block the sphenopalatine ganglion which is a bundle of nerves that includes nerves that cause head pain. This block is performed by spraying numbing medication into the back of the nasal cavity on both sides. This particular pain medication does not have the side effects discussed above. The purpose of the study is to see if this treatment will decrease pain without causing unwanted side effects. All patients in the study will receive standard pain medicine as needed for headache. Information will be collected from the patient's medical chart on the amount of pain medication used and the amount of pain the patient describes having. The average pain will be calculated for the first 24 hours the patient is in the hospital. At that point, the patient will receive pain medication sprayed into the back of the nasal cavity on both sides. Patients will also receive this treatment 3 days later. Following these treatments, information will be obtained on the average amount of pain, and how much other pain medication is used. The investigators will look at the amount of pain and the amount of other pain medicine used over the first 24 hours before the nasal pain medicine treatment and compare it to the time after the treatments to see if the amount of pain decreases and if the amount of other pain medicine needed decreases as well. Six months after discharge, the patient will be contacted by phone to find out more information about how much head pain they had after discharge from the hospital.
CONDITIONS
Official Title
Intranasal Sphenopalatine Ganglion Blockade for Headaches Following Aneurysmal Subarachnoid Hemorrhage
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older treated in the neurologic ICU for subarachnoid hemorrhage
- Hunt and Hess scale score of 0 to 3
- Able to verbally report headache
You will not qualify if you...
- Patients under 18 years of age
- Allergy to lidocaine
- Patients from vulnerable groups
- Hunt and Hess scale score of 4 to 5
- Unable to consent or mentally impaired
- Prisoners
- Pregnant patients
- History of recurrent nosebleeds
- Nasal deformities such as cleft lip and palate, choanal atresia, atrophic rhinitis, septal perforation, nasal or midface trauma
- Recent nasal or sinus surgery
- Bleeding disorders such as Von Willebrand's disease or hemophilia
- Severe respiratory distress
- Presence of angiofibroma, sinus tumor, or granulomatous disease of the nasopharynx
- Nasal congestion lasting more than 10 days, high fever, or abnormal nasal mucosa or mucus
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Miami Valley Hospital
Dayton, Ohio, United States, 45409
Actively Recruiting
Research Team
J
John B Terry, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here